OKUR insider transaction filings
OnKure Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-13. Screen OKUR transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-13 | 4/A | Manke Isaac — Director | Holdings only — no transactions reported | EDGAR |
| 2026-08-11 | 4 | Mathers Edward T — Director | Grant/award (A): 22,350 (derivative) @ $0 | EDGAR |
| 2026-08-11 | 4 | Phillips Andrew John — Director | Grant/award (A): 22,350 (derivative) @ $0 | EDGAR |
| 2026-08-11 | 4 | Ratcliffe Liam — Director | Grant/award (A): 22,350 (derivative) @ $0 | EDGAR |
| 2026-08-11 | 4 | Jansen Valerie Malyvanh — Director | Grant/award (A): 22,350 (derivative) @ $0 | EDGAR |
| 2026-08-11 | 4 | Manke Isaac — Director | Grant/award (A): 300,000 (derivative) @ $0 · Disposition to issuer (D): 15,300 (derivative) · Grant/award (A): 15,300 (derivative) | EDGAR |
| 2026-08-11 | 4 | GREY MICHAEL G — Director | Grant/award (A): 22,350 (derivative) @ $0 | EDGAR |
| 2026-08-11 | 4 | Carruthers R Michael — Director | Grant/award (A): 22,350 (derivative) @ $0 | EDGAR |
| 2026-08-11 | 4 | Hartley Dylan — Chief Scientific Officer | Grant/award (A): 50,000 (derivative) @ $0 · Disposition to issuer (D): 137,603 (derivative) · Grant/award (A): 137,603 (derivative) | EDGAR |
| 2026-08-11 | 4 | Leverone Jason A. — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 · Disposition to issuer (D): 5,781 (derivative) · Grant/award (A): 5,781 (derivative) · Disposition to issuer (D): 5,322 (derivative) · Grant/award (A): 5,322 (derivative) · Disposition to issuer (D): 130,611 (derivative) · +1 more | EDGAR |
| 2026-08-11 | 4 | Saccomano Nicholas A — President and CEO, Director | Grant/award (A): 150,000 (derivative) @ $0 · Disposition to issuer (D): 2,359 (derivative) · Grant/award (A): 2,359 (derivative) · Disposition to issuer (D): 1,485 (derivative) · Grant/award (A): 1,485 (derivative) · Disposition to issuer (D): 8,449 (derivative) · +5 more | EDGAR |
| 2026-08-11 | 4 | Agresta Samuel — Chief Medical Officer | Grant/award (A): 50,000 (derivative) @ $0 · Disposition to issuer (D): 18,588 (derivative) · Grant/award (A): 18,588 (derivative) · Disposition to issuer (D): 131,396 (derivative) · Grant/award (A): 131,396 (derivative) | EDGAR |
| 2026-06-24 | 4 | Leverone Jason A. — Chief Financial Officer | Sale (S): 303 @ $4.40 | EDGAR |
| 2026-06-24 | 4 | Saccomano Nicholas A — President and CEO, Director | Sale (S): 86 @ $4.40 | EDGAR |
| 2026-06-08 | 4 | Phillips Andrew John — Director | Grant/award (A): 7,650 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Jansen Valerie Malyvanh — Director | Grant/award (A): 7,650 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Carruthers R Michael — Director | Grant/award (A): 7,650 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Ratcliffe Liam — Director | Grant/award (A): 1,275 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Mathers Edward T — Director | Grant/award (A): 7,650 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | GREY MICHAEL G — Director | Grant/award (A): 7,650 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Hartley Dylan — Chief Scientific Officer | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Agresta Samuel — Chief Medical Officer | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Leverone Jason A. — Chief Financial Officer | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Saccomano Nicholas A — President and CEO, Director | Grant/award (A): 330,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Ratcliffe Liam — Director | Grant/award (A): 15,300 (derivative) @ $0 | EDGAR |
| 2026-03-24 | 4 | Leverone Jason A. — Chief Financial Officer | Sale (S): 301 @ $4.16 | EDGAR |
| 2026-03-24 | 4 | Saccomano Nicholas A — President and CEO, Director | Sale (S): 86 @ $4.16 | EDGAR |
| 2026-01-02 | 4 | Manke Isaac — Director | Grant/award (A): 5,258 @ $0 | EDGAR |
| 2026-01-02 | 4 | Mathers Edward T — Director | Grant/award (A): 3,911 @ $0 | EDGAR |
| 2025-12-23 | 4 | Leverone Jason A. — Chief Financial Officer | Sale (S): 302 @ $2.97 | EDGAR |
| 2025-12-23 | 4 | Saccomano Nicholas A — President and CEO, Director | Sale (S): 87 @ $2.97 | EDGAR |
| 2025-10-02 | 4 | Manke Isaac — Director | Grant/award (A): 5,545 @ $0 | EDGAR |
| 2025-10-02 | 4 | Mathers Edward T — Director | Grant/award (A): 4,125 @ $0 | EDGAR |
| 2025-09-24 | 4 | Leverone Jason A. — Chief Financial Officer | Sale (S): 303 @ $2.62 | EDGAR |
| 2025-09-24 | 4 | Saccomano Nicholas A — President and CEO, Director | Sale (S): 88 @ $2.62 | EDGAR |
| 2025-07-02 | 4 | Manke Isaac — Director | Grant/award (A): 6,311 @ $0 | EDGAR |
| 2025-07-02 | 4 | Mathers Edward T — Director | Grant/award (A): 4,694 @ $0 | EDGAR |
| 2025-06-25 | 4 | Leverone Jason A. — Chief Financial Officer | Sale (S): 303 @ $2.38 | EDGAR |
| 2025-06-25 | 4 | Saccomano Nicholas A — President and CEO, Director | Sale (S): 88 @ $2.38 | EDGAR |
| 2025-05-30 | 4 | Phillips Andrew John — Director | Grant/award (A): 7,650 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Jansen Valerie Malyvanh — Director | Grant/award (A): 7,650 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Carruthers R Michael — Director | Grant/award (A): 7,650 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Manke Isaac — Director | Grant/award (A): 7,650 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Mathers Edward T — Director | Grant/award (A): 7,650 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | GREY MICHAEL G — Director | Grant/award (A): 7,650 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Cormorant Asset Management, LP Cormorant Global Healthcare Master Fund, LP Cormorant Private Healthcare Fund III LP Cormorant Private Healthcare Fund IV LP Cormorant Private Healthcare Fund V LP Chen Bihua | Sale (S): 1,813,439 @ $1.85 | EDGAR |
| 2025-05-19 | 4 | ACORN BIOVENTURES, L.P. — 10% owner ACORN CAPITAL ADVISORS GP, LLC — 10% owner Hove Anders D — 10% owner | Purchase (P): 270,270 @ $1.85 · Purchase (P): 1,129,730 @ $1.85 | EDGAR |
| 2025-05-14 | 4 | Cormorant Asset Management, LP — 10% owner Cormorant Global Healthcare Master Fund, LP — 10% owner Cormorant Private Healthcare Fund III LP — 10% owner Cormorant Private Healthcare Fund IV LP — 10% owner Cormorant Private Healthcare Fund V LP — 10% owner Chen Bihua — 10% owner | Sale (S): 24,300 @ $1.99 | EDGAR |
| 2025-04-08 | 4 | Leverone Jason A. — Chief Financial Officer | Sale (S): 1,278 @ $3.33 · Sale (S): 1,844 @ $2.67 | EDGAR |
| 2025-04-08 | 4 | Saccomano Nicholas A — President and CEO, Director | Sale (S): 358 @ $3.33 · Sale (S): 516 @ $2.67 | EDGAR |
Recent 8-K events — OnKure Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=OKUR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →